-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers from the University of Texas and other institutions have recently developed a new IgM antibody therapy, which is more than 230 times more effective in neutralizing than traditional IgG antibody therapy
.
This IgM antibody can also effectively neutralize multiple virus variants
.
The research titled "Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants" was published in the journal Nature
.
Researchers modified IgM antibodies and found that in all cases, these antibodies were significantly more effective than standard IgG antibodies in neutralizing the COVID-19 virus
.
Among them, an antibody called IgM-14 showed a significant increase in efficacy against original strains and emerging variants (such as variants of concern currently found in the United Kingdom, South Africa, and Brazil)
.
In addition, when administered to the nasal cavity, the IgM antibody proved to be very effective in the prevention and treatment of mouse models
.
Professor Zhiqiang An from the University of Texas at Houston Health Sciences Center (UTHealth) said: “The high viral load in the respiratory tract is associated with severe disease and mortality in COVID-19 patients
.
Respiratory mucosal antibodies are used to clear SARS-CoV-2 infections.
The key to reducing the spread of viruses, and IgM antibodies are nature’s first line of defense against viruses and other pathogens
.
"He is also one of the corresponding authors of this article
.
At present, almost all antibodies used to neutralize the new coronavirus are IgG antibodies, which require high-dose intravenous injections and will not directly target the main parts of the virus infection
.
"SARS-CoV-2 has evolved multiple mutations that have severely impaired the neutralizing activity of many IgG monoclonal antibodies, including those that are undergoing clinical trials and authorized for emergency use
.
Therefore, the development of new antibodies that can overcome these challenges Therapy is an urgent but unmet need, and we are pleased with the data released today," Professor An said
.
"Integrating the advantages of multiple institutions from academia and industry is the key to quickly transforming ideas into therapeutic drug candidates
.
This is another successful example
.
Cross-institutional and academic-industrial cooperation should be expanded to other diseases Indications," said Dr.
Shi Pei-Yong from the University of Texas Medical Department
.
This IgM antibody has been licensed to biotechnology partner IGM Biosciences for drug development
.
Fred Schwarzer, CEO of IGM Biosciences, said: "The ability to use IgM antibodies that effectively neutralize SARS-CoV-2 and its multiple variants is a very exciting application of the IGM platform
.
" References Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Nature https://doi.
org/ 10.
1038/s41586-021-03673-2 (2021).
Source: BioTone
.
This IgM antibody can also effectively neutralize multiple virus variants
.
The research titled "Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants" was published in the journal Nature
.
Researchers modified IgM antibodies and found that in all cases, these antibodies were significantly more effective than standard IgG antibodies in neutralizing the COVID-19 virus
.
Among them, an antibody called IgM-14 showed a significant increase in efficacy against original strains and emerging variants (such as variants of concern currently found in the United Kingdom, South Africa, and Brazil)
.
In addition, when administered to the nasal cavity, the IgM antibody proved to be very effective in the prevention and treatment of mouse models
.
Professor Zhiqiang An from the University of Texas at Houston Health Sciences Center (UTHealth) said: “The high viral load in the respiratory tract is associated with severe disease and mortality in COVID-19 patients
.
Respiratory mucosal antibodies are used to clear SARS-CoV-2 infections.
The key to reducing the spread of viruses, and IgM antibodies are nature’s first line of defense against viruses and other pathogens
.
"He is also one of the corresponding authors of this article
.
At present, almost all antibodies used to neutralize the new coronavirus are IgG antibodies, which require high-dose intravenous injections and will not directly target the main parts of the virus infection
.
"SARS-CoV-2 has evolved multiple mutations that have severely impaired the neutralizing activity of many IgG monoclonal antibodies, including those that are undergoing clinical trials and authorized for emergency use
.
Therefore, the development of new antibodies that can overcome these challenges Therapy is an urgent but unmet need, and we are pleased with the data released today," Professor An said
.
"Integrating the advantages of multiple institutions from academia and industry is the key to quickly transforming ideas into therapeutic drug candidates
.
This is another successful example
.
Cross-institutional and academic-industrial cooperation should be expanded to other diseases Indications," said Dr.
Shi Pei-Yong from the University of Texas Medical Department
.
This IgM antibody has been licensed to biotechnology partner IGM Biosciences for drug development
.
Fred Schwarzer, CEO of IGM Biosciences, said: "The ability to use IgM antibodies that effectively neutralize SARS-CoV-2 and its multiple variants is a very exciting application of the IGM platform
.
" References Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
Nature https://doi.
org/ 10.
1038/s41586-021-03673-2 (2021).
Source: BioTone
